Bellicum Pharmaceuticals, Inc. (BLCM)
Chart Events
Performance Outlook
| Previous Close | 0.2000 |
| Open | 0.2000 |
| Bid | 0.0000 x 800 |
| Ask | 0.0000 x 800 |
| Day's Range | 0.2000 - 0.2491 |
| 52 Week Range | 0.0600 - 1.5000 |
| Volume | |
| Avg. Volume | 18,493 |
| Market Cap | 1.951M |
| Beta (5Y Monthly) | 1.59 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.7200 |
| Earnings Date | Nov 14, 2023 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
Fair Value
Subscribe to Yahoo Finance Plus to view Fair Value for BLCM
Related Research
- BELLICUM PHARMACEUTICALSAnalyst Report: Pfizer Inc.Pfizer is one of the world's largest pharmaceutical firms, with annual sales close to $50 billion (excluding COVID-19 product sales). While it historically sold many types of healthcare products and chemicals, now prescription drugs and vaccines account for the majority of sales. Top sellers include pneumococcal vaccine Prevnar 13, cancer drug Ibrance, and cardiovascular treatment Eliquis. Pfizer sells these products globally, with international sales representing close to 50% of total sales. Within international sales, emerging markets are a major contributor.RatingFair ValueEconomic Moat8 days agoMorningstar
ZacksBellicum (BLCM) Down on Ending Development of CAR-T Candidates
Following the decision to discontinue the development of pipeline candidates, Bellicum Pharmaceuticals (BLCM) is left with no candidate in clinical development. The stock is down 50% post the news.
ZacksIs Bellicum Pharmaceuticals (BLCM) Stock Outpacing Its Medical Peers This Year?
Here is how Bellicum Pharmaceuticals (BLCM) and Chemed (CHE) have performed compared to their sector so far this year.
GlobeNewswireBellicum Discontinues Phase 1/2 Trials and Initiates Evaluation of Strategic Alternatives
HOUSTON, March 14, 2023 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (Nasdaq: BLCM), today announced its decision to discontinue its ongoing Phase 1/2 clinical trials evaluating the safety and preliminary efficacy of its GoCAR-T cell product candidates in combination with rimiducid in heavily pre-treated cancer patients. The trials for BPX-601 and BPX-603 are being discontinued following the Company’s assessment of the risk/benefit profile of BPX-601 in combination with rimiducid. The most
